CD4 and neoplasm: Examination of T cells (CD3+/CD4+ and CD3+/CD8+) and NK cells (CD3-/NK1.1+), primarily responsible for anti-tumor effector immune function, revealed statistically significant increases in the numbers of CD4+ T cells (p=0.04) in LLC tumors (Figure 2A) and NK cells in MC-38 tumors (p=0.03) (Figure 2B). We did not find evidence of changes in myeloid or lymphoid cell percentages in the spleen (Figure S3).